GleamWall
中文EN

DARE Dare Bioscience, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1401914 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2,570.3%
TTM net income YoY39.4%
TTM EPS YoY66.7%
Revenue 3-yr CAGR12.2%
Net income 3-yr CAGR—

Margins

Gross margin26.4%
Operating margin-746.1%
Net margin-749.8%
FCF margin-1,279.2%
EBITDA margin-592.2%

Returns

ROE-407.1%
ROA-40.0%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets89.4%
Debt / equity0.00x
Current ratio1.23x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.66x
Accruals ratio26.4%
Payout ratio—
Capex / revenue34.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.03M$9,784
Cost of revenue$295,799$0
Gross profit$734,394$9,784
R&D expense$5.52M$14.31M
SG&A expense$8.76M$9.16M
Operating income-$13.55M-$23.45M
Pretax income-$13.54M-$4.05M
Income tax$0$0
Net income-$13.40M-$4.05M
EBITDA-$11.92M-$23.41M
EPS (basic)-1.20-0.48
EPS (diluted)-1.20-0.48
Weighted avg. shares (diluted)11.18M8.50M
Balance sheet
Cash & equivalents$24.71M$16.00M
Current assets$27.06M$18.45M
PP&E, net$1.56M$1.34M
Total assets$32.47M$22.10M
Current liabilities$23.69M$21.61M
Short-term debt—$4,054
Total liabilities$29.63M$28.11M
Shareholders' equity$2.84M-$6.01M
Shares outstanding14.50M8.70M
Cash flow statement
Operating cash flow-$9.89M$5.47M
Capital expenditure$385,278$573,046
Free cash flow-$10.27M$4.90M
Investing cash flow-$385,278-$573,046
Financing cash flow$19.28M$354,522
Depreciation & amortization$1.63M$42,325
Stock-based compensation$1.50M$2.20M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.